Key facts
- This page summarizes Kevin Damour's Form 4 filing for Brooklyn ImmunoTherapeutics, Inc. (ERNA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Jun 2022, 20:01.
Kevin Damour - 28 Jun 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- ERNA
- Reported as of
- 28 Jun 2022
- Net transaction value
- -$3,363
- SEC form
- 4
- Accepted by SEC
- 29 Jun 2022, 20:01:50 UTC
- Prior SEC filing
- 17 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kevin D'Amour
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kevin Damour filed Form 4 for Brooklyn ImmunoTherapeutics, Inc. (ERNA) on 29 Jun 2022.
Change
- Previous filing in this sequence was filed on 17 Mar 2022.
- Current net transaction value: -$3,363.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ERNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +17,573
- Change %
- Price
- Shares after
- 17,573
- Date
- 28 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
ERNA
transaction
Common Stock
Tax liability
- Transaction value
- $3,363
- Shares
- -6,077
- Change %
- -35%
- Price
- $0.5534*
- Shares after
- 11,496
- Date
- 28 Jun 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ERNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -17,573
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 52,717
- Date
- 28 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,573
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit converts into one share of common stock.
Footnote F2
On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.